SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy

Neoplasma

Volumn 59, Issue 5, 2012, Pages 486-493

  Shen, G ^a   Li, Y ^a   Du, T ^a   Shi, G ^a   Dai, L ^a   Chen, X ^a   Zheng, R ^a   Li, W ^a   Su, X ^a   Zhang, S ^a   Wei, Y ^a   Yang, S ^a   Deng, H ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Chemotherapy; Hypoxia; Metastasis; Vascular normalization

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; DOXORUBICIN; IRINOTECAN; PIMONIDAZOLE; SKLB1002; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; VASCULOTROPIN RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMOTHERAPY; DRUG EFFECT; HISTOPATHOLOGY; HYPOXIA; IMMUNOFLUORESCENCE TEST; METASTASIS; NEOPLASM; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; VASCULAR NORMALIZATION; ANIMAL; ANOXIA; BAGG ALBINO MOUSE; CANCER INVASION; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; TUMOR CELL CULTURE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG SYNERGISM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866757805     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_062     Document Type: Article

References (24)

1. SIEGEL R, WARD E, BRAWLEY O, JEMAL A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236. http://dx.doi.org/10.3322/caac.20121
2. HANAHAN D and WEINBERG RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674. http://dx.doi.org/10.1016/j.cell.2011.02.013
3. KERBEL RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049. http://dx.doi.org/10.1056/NEJMra0706596
4. BICKNELL R and HARRIS AL. Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis. Semin Cancer Biol 1992; 3: 399-407.
5. BERGERS G AND HANAHAN D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603. http://dx.doi.org/10.1038/nrc2442
6. HURWITZ H, FEHRENBACHER L, NOVOTNY W, CARTWRIGHT T, HAINSWORTH J et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. http://dx.doi.org/10.1056/NEJMoa032691
7. JAIN RK. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science 2005; 307: 58-62. http://dx.doi.org/10.1126/science.1104819
8. ESCORCIA FE, HENKE E, MCDEVITT MR, VILLA CH, SMITH-JONES P et al. Selective killing of tumor neovas-culature paradoxically improves chemotherapy delivery to tumors. Cancer Res 2010; 70: 9277-9286. http://dx.doi.org/10.1158/0008-5472.CAN-10-2029
9. MAITY A AND BERNHARD EJ. Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy. Cancer Res 2010; 70: 2141-2145. http://dx.doi.org/10.1158/0008-5472.CAN-09-3615
10. ZHANG S, CAO Z, TIAN H, SHEN G, MA Y et al. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res 2011; 17: 4439-4450. http://dx.doi.org/10.1158/1078-0432.CCR-10-3109
11. PIROT N, DELEUZE V, EL-HAJJ R, DOHET C, SABLITZKY F et al. LYL1 activity is required for the maturation of newly formed blood vessels in adulthood. Blood 2010; 115: 5270-5279. http://dx.doi.org/10.1182/blood-2010-03-275651
12. BHATTACHARYA A, SESHADRI M, OVEN SD, TOTH K, VAUGHAN MM et al. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin. Cancer Res 2008; 14: 3926-3932. http://dx.doi.org/10.1158/1078-0432.CCR-08-0212
13. WINKLER F, KOZIN SV, TONG RT, CHAE SS, BOOTH MF et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6: 553-563.
14. SATO Y. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy. Cancer Sci 2011; 102: 1253-1256. http://dx.doi.org/10.1111/j.1349-7006.2011.01929.x
15. DICKSON PV, HAMNER JB, SIMS TL, FRAGA CH, NG CY et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13: 3942-3950. http://dx.doi.org/10.1158/1078-0432.CCR-07-0278
16. TONG RT, BOUCHER Y, KOZIN SV, WINKLER F, HICKLIN DJ et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 3731-3736. http://dx.doi.org/10.1158/0008-5472.CAN-04-0074
17. CERNIGLIA GJ, PORE N, TSAI JH, SCHULTZ S, MICK R et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS ONE 2009; 4: e6539. http://dx.doi.org/10.1371/journal.pone.0006539
18. QAYUM N, IM J, STRATFORD MR, BERNHARD EJ, MCKENNA WG et al. Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases Doxorubicin delivery in vivo. Clin Cancer Res 2012; 18: 161-169. http://dx.doi.org/10.1158/1078-0432.CCR-11-1413
19. PAEZ-RIBES M, ALLEN E, HUDOCK J, TAKEDA T, OKUYAMA H et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231. http://dx.doi.org/10.1016/j.ccr.2009.01.027
20. EBOS JM, LEE CR, CRUZ-MUNOZ W, BJARNASON GA, CHRISTENSEN JG et al. Accelerated metastasis after shortterm treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239. http://dx.doi.org/10.1016/j.ccr.2009.01.021
21. VAN LUMMEL M, VAN BLITTERSWIJK WJ, VINK SR, VELDMAN RJ, VAN DER VALK MA et al. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors. FASEB J 2011; 25: 280-289. http://dx.doi.org/10.1096/fj.10-163709
22. SINGH JAGGI J, HENKE E, SESHAN SV, KAPPEL BJ, CHATTOPADHYAY Det al. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS ONE 2007; 2: e267. http://dx.doi.org/10.1371/journal.pone.0000267
23. SEMENZA GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732. http://dx.doi.org/10.1038/nrc1187
24. ERLER JT, BENNEWITH KL, NICOLAU M, DORNHOFER N, KONG C et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440: 1222-1226. http://dx.doi.org/10.1038/nature04695